BioCentury
ARTICLE | Company News

FDA to discuss Novo's insulin products

October 10, 2012 1:18 AM UTC

FDA confirmed the Nov. 8 meeting date for the Endocrinologic and Metabolic Drugs Advisory Committee to discuss NDAs from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) for insulin Degludec and insulin Degludec/...